Delivery Order SPE2DB20D9329-SPE2DB22FD4FY
Award Date
1/18/22
Potential Completion Date
2/8/22
Potential Value
$20K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a $15,474.00 firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) to supply Xolair 150 mg/1.2 ml powder vials. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) with DLA under the SPE2DB program, which allows the agency to issue delivery orders for a wide range of pharmaceutical products to support the medical supply needs of Department of Defense...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The $9,671.25 firm fixed-price delivery order is for the pharmaceutical product XOLAIR 150 MG/ML SYRINGEML, with a completion date of June 4, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue delivery...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The $6,963.30 firm fixed-price delivery order is for the pharmaceutical product Xolair 150 mg/mL syringe. This award is part of DMS Pharmaceutical Group's larger $499,999,999 indefinite delivery contract (IDC) with the DLA to provide a wide range of pharmaceutical items, including both common and specialized medications, to support...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The $13,539.75 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, with a period of performance through September 17, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The $74,275.20 firm fixed-price delivery order covers the supply of Xolair 150 mg/1.2 ml powder vials to support the recurring medical needs of military healthcare facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA, which allows the agency to issue...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, was issued by the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense (DoD). The $4,642.20 firm fixed-price delivery order is for the supply of XOLAIR 150 MG/ML SYRINGEML, a specialty pharmaceutical product, to fulfill the recurring medical supply needs of military health facilities. The award is not associated with any set-aside program. DMS Pharmaceutical Group holds a...
This contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order valued at $74,275.20 issued under the Defense Logistics Agency's (DLA) SPE2DB Indefinite Delivery Contract. The contract is for the provision of pharmaceutical products, including Xolair 150 mg/1.2 ml powder, to support the medical supply needs of military healthcare facilities. This single-award IDC, valued at $499,999,999, enables the DLA to issue firm fixed-price...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order under the Defense Logistics Agency's (DLA) SPE2DB program. The $4,642.20 firm fixed-price award is for the supply of a specific pharmaceutical product, XOLAIR 150 MG/ML SYRINGE, to support the recurring medical needs of Department of Defense (DoD) healthcare facilities. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a firm fixed-price Delivery Order (SPE2DB23FQ60G) valued at $15,474.00 for the supply of XOLAIR 150 MG/ML syringes. The contract is awarded under the Defense Logistics Agency's (DLA) SPE2DB program, a $499,999,999 indefinite delivery contract (IDC) that runs through December 31, 2025. This IDC allows the DLA to issue delivery orders to DMS Pharmaceutical Group for a...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a delivery order issued by the Defense Logistics Agency (DLA) under the SPE2DB Indefinite Delivery Contract (IDC). The $74,275.20 firm fixed-price award is for the supply of Xolair 150 mg/1.2 ml powder vials, a specialized pharmaceutical product used for medical treatments. The IDC held by DMS Pharmaceutical Group Inc. is valued at $499,999,999 and covers a comprehensive range of branded and generic...